Update on neuromuscular pharmacology

Current Opinion in Anaesthesiology

Volumn 22, Issue 4, 2009, Pages 483-490

  Naguib, Mohamed ^a   Brull, Sorin J ^b  

^a UNIVERSITY OF TEXAS   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Antagonism; AV002; Cysteine; Gantacurium; Neuromuscular blockade; Neuromuscular blockers; Sugammadex

Indexed keywords

AV 002; AV 430; CHOLINESTERASE INHIBITOR; CYSTEINE; EXCITOTOXIN; FUMARIC ACID; GAMMA CYCLODEXTRIN; GANTACURIUM; GLUTATHIONE; NEOSTIGMINE; NEUROMUSCULAR BLOCKING AGENT; ROCURONIUM; SUGAMMADEX; SULFATE; SUXAMETHONIUM; TAURINE; UNCLASSIFIED DRUG; VECURONIUM;

ANTIOXIDANT ACTIVITY; BEHAVIOR DISORDER; BRONCHOSPASM; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CORONARY HEMODYNAMICS; COUGHING; CREATININE CLEARANCE; DOSE RESPONSE; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG APPROVAL; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DECOMPOSITION; DRUG DEGRADATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG HYDROLYSIS; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG SCREENING; DRUG STRUCTURE; ENDOTRACHEAL INTUBATION; ENZYME ACTIVITY; GENERAL ANESTHESIA; GLUTATHIONE METABOLISM; HUMAN; HYDROPHOBICITY; HYPOGLYCEMIA; MEAN ARTERIAL PRESSURE; MOLECULAR WEIGHT; MOTOR DYSFUNCTION; NEUROTOXICITY; NONHUMAN; PARENTERAL NUTRITION; PRICK TEST; PRIORITY JOURNAL; RACEMIZATION; REVIEW; SKIN TEST; URINARY EXCRETION;

ANIMALS; CHOLINESTERASE INHIBITORS; CYSTEINE; GAMMA-CYCLODEXTRINS; HUMANS; ISOQUINOLINES; NEUROMUSCULAR NONDEPOLARIZING AGENTS;

EID: 68949113808     PISSN: 09527907     EISSN: None     Source Type: Journal    
DOI: 10.1097/ACO.0b013e32832b8cff     Document Type: Review

References (73)

1. Läwen A. About the connection of local anaesthesia with general anaesthesia; about high extradural anaesthesia and epidural injection of anaesthesizing solutions for 'stomach crisis'. Beitr Klin Chir 1912; 80:168-180.
2. Griffith H, Johnson GE. The use of curare in general anesthesia. Anesthesio-logy 1942; 3:418-420.
3. Thesleff S. Succinylcholine iodide: studies on its pharmacological properties and clinical use. Acta Physiol Scand 1952; 27:1-36.
4. Foldes FF, McNall PG, Borrego-Hinojosa JM. Succinylcholine, a new approach to muscular relaxation in anaesthesiology. N Engl J Med 1952; 247:596-600.
5. Baird WL, Reid AM. The neuromuscular blocking properties of a new steroid compound, pancuronium bromide, A pilot study in man. Br J Anaesth 1967; 3910:775-780.
6. Savage DS, Sleigh T, Carlyle I. The emergence of ORG NC 45, 1 - [2 beta,3 alpha,5 alpha,16 beta,17 beta)-3, 17-bis(acetyloxy)-2-(1-piperidinyl)-andro- stan-16-yl]-1-methylpiperidinium bromide, from the pancuronium series. Br J Anaesth 1980; 52 (Suppl 1):3S-9S.
7. Stenlake JB, Waigh RD, Dewar GH, et al. Biodegradable neuromuscular blocking agents. Part 4: Atracurium besylate and related polyalkylylene di-esters. Eur J Med Chem 1981; 16:515.
8. Stenlake JB, Waigh RD, Urwin J, et al. Atracurium: conception and inception. Br J Anaesth 1983; 55 (Suppl 1):3S-10S.
9. Savarese JJ, Ali HH, Basta SJ, etal. The clinical neuromuscular pharmacology of mivacurium chloride (BW B1090U). A short-acting nondepolarizing ester neuromuscular blocking drug. Anesthesiology 1988; 685:723-732.
10. Wierda JM, de Wit AP, Kuizenga K, et al. Clinical observations on the neuromuscular blocking action of Org 9426, a new steroidal nondepolarizing agent. Br J Anaesth 1990; 644:521-523.
11. Bovet D. Some aspects of the relationship between chemical constitution and curare-like activity. Ann NY Acad Sci 1951; 54:407-437.
12. Alcuronium (Alloferin): a new neuromuscular blocking agent. Drug Ther Bull 1967; 517:67-68.
13. Hughes R, Payne JP, Sugai N. Studies on fazadinium bromide (ah 8165): a new nondepolarizing neuromuscular blocking agent. Can Anaesth Soc J 1976; 231:36-47.
14. Karpati E, Biro K. Pharmacological study of a new competitive neuromuscular blocking steroid, pipecurium bromide. Arzneimittelforschung 1980; 302a: 346-357.
15. Basta SJ, Savarese JJ, Ali HH, et al. Clinical pharmacology of doxacurium chloride. A new long-acting nondepolarizing muscle relaxant. Anesthesiology 1988; 694:478-486.
16. Wastila WB, Maehr RB, Turner GL, et al. Comparative pharmacology of cisatracurium (51W89), atracurium, and five isomers in cats. Anesthesiology 1996; 851:169-177.
17. Wierda JM, van den Broek L, Proost JH, et al. Time course of action and endotracheal intubating conditions of Org 9487, a new short-acting steroidal muscle relaxant; a comparison with succinylcholine. Anesth Analg 1993; 773:579-584.
18. Belmont MR, Lien CA, Tjan J, etal. Clinical pharmacology of GW280430A in humans. Anesthesiology 2004; 1004:768-773.
19. Viby-Mogensen J, Jorgensen BC, Ording H. Residual curarization in the recovery room. Anesthesiology 1979; 506:539-541.
20. Debaene B, Plaud B, Dilly MP, et al. Residual paralysis in the PACU after a single intubating dose of nondepolarizing muscle relaxant with an intermediate duration of action. Anesthesiology 2003; 985:1042-1048.
21. Murphy GS, Szokol JW, Marymont JH, etal. Residual neuromuscular blockade •• and critical respiratory events in the postanesthesia care unit. Anesth Analg 2008; 1071:130-137.
22. Eriksson LI, Sundman E, Olsson R, etal. Functional assessment of the pharynx at rest and during swallowing in partially paralyzed humans: simultaneous videomanometry and mechanomyography of awake human volunteers. Anesthesiology 1997; 875:1035-1043.
23. Sundman E, Witt H, Olsson R, et al. The incidence and mechanisms of pharyngeal and upper esophageal dysfunction in partially paralyzed humans: pharyngeal videoradiography and simultaneous manometry after atracurium. Anesthesiology 2000; 924:977-984.
24. Eriksson LI. The effects of residual neuromuscular blockade and volatile anesthetics on the control of ventilation. Anesth Analg 1999; 891:243-251.
25. Bartkowski RR. Incomplete reversal of pancuronium neuromuscular blockade by neostigmine, pyridostigmine, and edrophonium. Anesth Analg 1987; 667:594-598.
26. Beemer GH, Bjorksten AR, Dawson PJ, etal. Determinants of the reversal time of competitive neuromuscular block by anticholinesterases. Br J Anaesth 1991; 664:469-475.
27. Brull SJ, Naguib M, Miller RD. Residual neuromuscular block: rediscovering •• the obvious. Anesth Analg 2008; 1071:11-14.
28. Savarese JJ, Belmont MR, Hashim MA, et al. Preclinical pharmacology of GW280430A (AV430A) in the rhesus monkey and in the cat: a comparison with mivacurium. Anesthesiology 2004; 1004:835-845.
29. Boros EE, Samano V, Ray JA, et al. Neuromuscular blocking activity and therapeutic potential of mixed-tetrahydroisoquinolinium halofumarates and halosuccinates in rhesus monkeys. J Med Chem 2003; 4612:2502-2515.
30. Savarese JJ, Belmont MR, Kraus K, et al. AV002: A Promising Cysteine-Reversible Intermediate Duration Neuromuscular Blocker in Rhesus Monkeys. ASA Meeting 2007:A986.
31. Sunaga H, Malhotora JK, Savarese JJ, etal. Dose Response Relationship for Cysteine Reversal of the Novel Muscle Relaxant AV002 in Dogs. ASA Annual Meeting 2008: A364.
32. Naguib M, el-Gammal M, Daoud W, et al. Human plasma cholinesterase for antagonism of prolonged mivacurium-induced neuromuscular blockade. Anesthesiology 1995; 825:1288-1292.
33. Belmont MR, Horochiwsky Z, Eliazo RF, et al. Reversal of AV430A with cysteine in rhesus monkeys. Anesthesiology 2004:A-1180.
34. Bom A, Bradley M, Cameron K, et al. A novel concept of reversing neuromuscular block: chemical encapsulation of rocuronium bromide by a cyclo-dextrin-based synthetic host. Angew Chem 2002; 412:266-270.
35. Adam JM, Bennett DJ, Bom A, et al. Cyclodextrin-derived host molecules as reversal agents for the neuromuscular blocker rocuronium bromide: synthesis and structure-activity relationships. J Med Chem 2002; 459:1806-1816.
36. Tarver GJ, Grove SJ, Buchanan K, et al. 2-O-substituted cyclodextrins as reversal agents for the neuromuscular blocker rocuronium bromide. Bioorg Med Chem 2002; 106:1819-1827.
37. Cameron KS, Clark JK, Cooper A, et al. Modified gamma-cyclodextrins and their rocuronium complexes. Org Lett 2002; 420:3403-3406 www.gangwalchem.com/ CYCLODEXTRIN.html. [Accessed 17 November 2008]
38. Shields M, Giovannelli M, Mirakhur RK, et al. Org 25969 (sugammadex), a selective relaxant binding agent for antagonism of prolonged rocuronium-induced neuromuscular block. Br J Anaesth 2006; 961:36-43.
39. Sorgenfrei IF, Norrild K, Larsen PB, et al. Reversal of rocuronium-induced neuromuscular block by the selective relaxant binding agent sugammadex: a dose-finding and safety study. Anesthesiology 2006; 1044:667-674.
40. Naguib M. Sugammadex: another milestone in clinical neuromuscular pharmacology. Anesth Analg 2007; 1043:575-581.
41. Epemolu O, Bom A, Hope F, et al. Reversal of neuromuscular blockade and simultaneous increase in plasma rocuronium concentration after the intravenous infusion of the novel reversal agent Org 25969. Anesthesiology 2003; 993:632-637.
42. Naguib M. Sugammadex may replace best clinical practice: a misconception. Anesth Analg 2007; 1055:1506-a-1507.
43. Gijsenbergh F, Ramael S, Houwing N, et al. First human exposure of Org 25969, a novel agent to reverse the action of rocuronium bromide. Anesthesiology 2005; 1034:695-703.
44. de Boer HD, van Egmond J, van de Pol F, et al. Chemical encapsulation of rocuronium by synthetic cyclodextrin derivatives: reversal of neuromuscular block in anaesthetized Rhesus monkeys. Br J Anaesth 2006; 962:201-206.
45. de Boer HD, van Egmond J, van de Pol F, et al. Reversal of profound rocuronium neuromuscular blockade by sugammadex in anesthetized rhesus monkeys. Anesthesiology 2006; 1044:718-723.
46. de Boer HD, van Egmond J, van de Pol F, et al. Sugammadex, a new reversal agent for neuromuscular block induced by rocuronium in the anaesthetized Rhesus monkey. Br J Anaesth 2006; 964:473-479.
47. Eleveld DJ, Kuizenga K, Proost JH, et al. A temporary decrease in twitch response during reversal of rocuronium-induced muscle relaxation with a small dose of sugammadex. Anesth Analg 2007; 1043:582-584.
48. Zhang MQ. Drug-specific cyclodextrins: the future of rapid neuromuscular block reversal? Drugs Future 2003; 28:347-354.
49. http://www.emea.europa.eu/humandocs/PDFs/EPAR/bridion/H-885-PI-en.pdf. [Accessed 10 November 2008]
50. Proost JH, Eriksson LI, Mirakhur RK, et al. Urinary, biliary and faecal excretion of rocuronium in humans. Br J Anaesth 2000; 855:717-723.
51. Sparr HJ, Vermeyen KM, Beaufort AM, et al. Early reversal of profound rocuronium-induced neuromuscular blockade by sugammadex in a randomized multicenter study: efficacy, safety, and pharmacokinetics. Anesthesiology 2007; 1065:935-943.
52. Staals LM, Snoeck MM, HunterJM, etal. Pharmacokinetics of rocuronium and sugammadex in patients with normal and impaired renal function. 13th World Congress of Anesthetists (WCA), Cape Town, South Africa, March 2-7, 2008.
53. Naguib M, Brull SJ. Sugammadex: a novel selective relaxant binding agent. Expert Rev Clin Pharmacol 2009; 2:37-53.
54. Rao AM, Drake MR, Stipanuk MH. Role of the transsulfuration pathway and of gamma-cystathionase activity in the formation of cysteine and sulfate from methionine in rat hepatocytes. J Nutr 1990; 1208:837-845.
55. Friedman M. Formation, nutritional value, and safety of D-amino acids. Adv Exp Med Biol 1991; 289:447-481.
56. Stipanuk MH. Sulfur amino acid metabolism: pathways for production and removal of homocysteine and cysteine. Annu Rev Nutr 2004; 24:539-577.
57. Coloso RM, Drake MR, Stipanuk MH. Effect of bathocuproine disulfonate, a copper chelator, on cyst(e)ine metabolism by freshly isolated rat hepatocytes. Am J Physiol 1990; 2593 (Pt 1):E443-450.
58. Weinstein CL, Haschemeyer RH, Griffith OW. In vivo studies of cysteine metabolism. Use of D-cysteinesulfinate, a novel cysteinesulfinate decarbox-ylase inhibitor, to probe taurine and pyruvate synthesis. J Biol Chem 1988; 26332:16568-16579.
59. Nakamura H, Kajikawa R, Ubuka T. A study on the estimation of sulfur-containing amino acid metabolism by the determination of urinary sulfate and taurine. Amino Acids 2002; 234:427-431.
60. Savarese JJ, Belmont MR, savard PR, et al. The Dose-Response for Immediate Reversal of AV 002 by Cysteine in the Rhesus Monkey. ASA Annual Meeting 2008:A1403.
61. Sunaga H, Malhotora JK, Savarese JJ, etal. Cardiovascular Effects of Cysteine Used for Reversal of Novel Neuromuscular Blocking Drugs in Dogs. ASA Annual Meeting 2008:A367.
62. Olney JW, Ho OL Brain damage in infant mice following oral intake of glutamate, aspartate or cysteine. Nature 1970 2275258: 609-611.
63. Olney JW, Ho OL, Rhee V, etal. Cysteine-induced brain damage in infant and fetal rodents. Brain Res 1972; 451:309-313.
64. Karlsen RL, Grofova I, Malthe-Sorenssen D, et al. Morphological changes in rat brain induced by L-cysteine injection in newborn animals. Brain Res 1981; 2081:167-180.
65. Misra CH. Is a certain amount of cysteine prerequisite to produce brain damage in neonatal rats? Neurochem Res 1989; 143:253-257.
66. Pean AR, Parsons RB, Waring RH, et al. Toxicity of sulphur-containing compounds to neuronal cell lines. J Neurol Sci 1995; 129 (Suppl):107-108.
67. Shapre LG, Olney JW, Ohlendorf C, et al. Brain damage and associated behavioral deficits following the administration of L-cysteine to infant rats. Pharmacol Biochem Behav 1975; 32:291-298.
68. Nath KA, Salahudeen AK. Autoxidation of cysteine generates hydrogen peroxide: cytotoxicity and attenuation by pyruvate. Am J Physiol 1993; 2642 (Pt2):F306-314.
69. Janaky R, Varga V, Hermann A, et al. Mechanisms of L-cysteine neurotoxicity. Neurochem Res 2000; 259-10:1397-1405.
70. Gazit V, Ben-Abraham R, Coleman R, et al. Cysteine-induced hypoglycemic brain damage: an alternative mechanism to excitotoxicity. Amino Acids 2004; 262:163-168.
71. Laine L, Shulman RJ, Pitre D, et al. Cysteine usage increases the need for acetate in neonates who receive total parenteral nutrition. Am J Clin Nutr 1991; 543:565-567.
72. Cammu G, De Witte J, De Veylder J, etal. Postoperative residual paralysis in outpatients versus inpatients. Anesth Analg 2006; 1022:426-429.
73. Kopman AF, Ng J, Zank LM, et al. Residual postoperative paralysis. Pancur-onium versus mivacurium, does it matter? Anesthesiology 1996; 856:1253-1259.